Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Leniolisib Phosphate

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pharming Receives FDA Acceptance of sNDA Resubmission for Joenja
    Pharming Receives FDA Acceptance of sNDA Resubmission for Joenja

    04 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/04/3306506/0/en/pharming-announces-u-s-fda-acceptance-of-snda-resubmission-for-joenja-leniolisib-to-treat-children-aged-4-to-11-years-with-apds.html

    GLOBENEWSWIRE
    04 Jun 2026
    Share Share
    European Commission Approves Joenja for APDS in EU
    European Commission Approves Joenja for APDS in EU

    22 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/22/3300332/0/en/european-commission-grants-marketing-authorization-to-pharming-s-joenja-leniolisib-the-first-approved-treatment-for-apds-in-the-european-union.html

    GLOBENEWSWIRE
    22 May 2026
    Share Share
    Pharming receives positive CHMP opinion for Joenja (leniolisib)
    Pharming receives positive CHMP opinion for Joenja (leniolisib)

    27 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/27/3263555/0/en/Pharming-Group-receives-positive-CHMP-opinion-for-Joenja-leniolisib-for-the-treatment-of-APDS-in-adult-and-pediatric-patients-12-years-and-older.html

    GLOBENEWSWIRE
    27 Mar 2026
    Share Share
    Pharming Group Gets FDA Complete Response Letter For Joenja
    Pharming Group Gets FDA Complete Response Letter For Joenja

    01 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/01/3229924/0/en/Pharming-Group-receives-Complete-Response-Letter-from-U-S-FDA-for-sNDA-for-Joenja-leniolisib-in-children-aged-4-to-11-years-with-APDS.html

    GLOBENEWSWIRE
    01 Feb 2026
    Share Share
    Pharming Group's Leniolisib For APDS In Children Accepted By FDA
    Pharming Group's Leniolisib For APDS In Children Accepted By FDA

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159182/0/en/Pharming-Group-announces-U-S-FDA-acceptance-and-Priority-Review-of-supplemental-New-Drug-Application-for-leniolisib-in-children-with-APDS-aged-4-to-11-years.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    Pharming Group starts Phase II trial of leniolisib for CVID
    Pharming Group starts Phase II trial of leniolisib for CVID

    20 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/20/3045939/0/en/Pharming-Group-announces-first-patient-dosed-in-Phase-II-clinical-trial-of-leniolisib-for-common-variable-immunodeficiency-CVID-with-immune-dysregulation.html

    GLOBENEWSWIRE
    20 Mar 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.